BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...lead for inflammation at Amgen Inc. (NASDAQ:AMGN). Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) hired Gad...
BioCentury | Mar 1, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

...α-synuclein. MeiraGTx Holdings plc (NASDAQ:MGTX) has conducted Phase II testing of AAV-GAD, which delivers the GAD...
...chronic pain that are in preclinical testing. Targets: DDC (AADC) - Dopa decarboxylase; GAD - Glutamic acid decarboxylase...
BioCentury | Mar 1, 2019
Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

...includes two candidates in Phase I/II testing: radiation-induced xerostomia therapy AAV-AQP1 and Parkinson's disease candidate AAV-GAD...
...Management also participated in the placement. MeiraGTx Holdings plc (NASDAQ:MGTX), New York, N.Y. Elizabeth S. Eaton AAV-AQP1 (A00X) AAV-GAD...
BioCentury | Feb 27, 2019
Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

...includes two candidates in Phase I/II testing: radiation-induced xerostomia therapy AAV-AQP1 and Parkinson's disease candidate AAV-GAD...
...OrbiMed Advisors and 683 Capital Management also participated in the placement. Elizabeth S. Eaton AAV-AQP1 (A00X) AAV-CNGA3 (A003) AAV-CNGB3 (A002) AAV-GAD...
BioCentury | Feb 23, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

...α-synuclein. MeiraGTx Holdings plc (NASDAQ:MGTX) has conducted Phase II testing of AAV-GAD, which delivers the GAD...
...chronic pain that are in preclinical testing. Targets: DDC (AADC) - Dopa decarboxylase; GAD - Glutamic acid decarboxylase Mark...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...at NLS Pharma Group (Stans, Switzerland). Cellular metabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Gad...
BioCentury | Aug 31, 2018
Financial News

Y-mAbs aims for $92M IPO

...Cheung; Peter Bang; Sofinnova Partners; and founder, Chairman, President and Head of Business Development Thomas Gad...
BioCentury | Aug 24, 2018
Financial News

Y-mAbs aiming for $92M IPO

...Cheung; Peter Bang; Sofinnova Partners; and founder, Chairman, President and Head of Business Development Thomas Gad...
BioCentury | Jul 13, 2018
Clinical News

Janssen's esketamine meets in Phase III to prevent treatment-resistant depression relapse

...Depression Rating Scale (MADRS), patient-reported outcomes, clinical global impression of severity (CGI-S), Generalized Anxiety Disorder (GAD-7...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...applicable PUBLICATION DETAILS: Huang, Y. et al. Genes Dev. ; published online June 26, 2018 doi:10.1101/gad.314815.118...
Items per page:
1 - 10 of 437